Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD ... becomes more evident when compared to its rival, Amgen Inc. (AMGN), which gained 14.4% over the past 52 weeks and 21.5 ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Amgen profits rise, next MariTide studies ... Gilead 3rd-quarter results beat Wall Street estimates, raises outlook Gilead Sciences reported third-quarter financial results that handily beat ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' rating.

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal. MiroBio was formed in 2019 to ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...

Gilead Sciences beat analysts’ revenue expectations ... beating analysts’ expectations by 1.9%, and Amgen reported revenues up 10.9%, topping estimates by 2.6%. AbbVie traded up 8.3% following ...